Public Hearing | In Person
Event Title
FDA's Opioid Policy Steering Committee - Prescribing Intervention - Exploring a Strategy for Implementation
January 16, 2018
- Date:
- January 16, 2018
- Website:
- https://www.eventbrite.com/e/public-meeting-assessment-of-fda-hiring-and-retention-tickets-38228383123
Meeting Date
January 30, 2018
Meeting Location
FDA White Oak Campus
10903 New Hampshire Avenue
Building 31 Conference Center
the Great Room B-C
Silver Spring, MD 20993-0002
The entrance for public meeting participants (non-FDA employees or contractors) is through Building 1, where routine security check procedures will be performed. For parking and security information, please refer to Public Meetings at the FDA White Oak Campus.
Background Information
Registration
If you wish to attend the public meeting (either in person or via webcast) and/or present at the meeting, please register by January 16, 2018.
If you need special accommodations due to a disability, please contact Kathleen Davies at 301-796-2205 or kathleen.davies@fda.hhs.gov at least 7 days before the meeting.
Webcast
View the recorded webcast of the event:
Submitting Comments
Regardless of attendance at the public meeting, you can submit electronic or written comments to the public docket by March 16, 2018. Submit electronic comments to Regulations.gov. Submit written comments to the Division of Docket’s Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852. Comments received by mail/hand delivery/courier (for written/paper submissions) will be considered timely if they are postmarked or the delivery service acceptance receipt is on or before that date.
All comments must be identified with the docket number FDA-2017-N-6502. The FDA may post, without change, all comments received to Regulations.gov, including any personal information provided.
Questions
If you have questions about registering for the meeting, contact Kathleen Davies, U.S. Food and Drug Administration, 10903 New Hampshire Ave., Silver Spring, MD 20993, phone: 301-796-2205, email: kathleen.davies@fda.hhs.gov.